ClinicalTrials.gg
RecruitingNCT06062303ANDROMEDA-FRUpdated Dec 5, 2024

Hemodynamic Phenotype-Based,Capillary Refill Time-Targeted Resuscitation In Early Septic Shock:ANDROMEDA-SHOCK-2

An interventional study of Usual care (UC) in Intensive Care Unit Acquired Weakness and Shock, Septic, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-05.

Sponsored by Assistance Publique - Hôpitaux de Paris · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as recruiting.
  • Started Feb 2024; still recruiting 2 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 30 studies in Shock, Septic by Assistance Publique - Hôpitaux de Paris — 15 open to participants now, 16 under way, 3 of them phase 3. Shock, Septic · Assistance Publique - Hôpitaux de Paris.

Planned enrollment
12th of 17
180 · median 210
Started
2024
with 2 others
No phase
8 of 30
5 open now
Primary completion
2025-12
later than 3 of 15 live
Registered
21st of 30
by date

Among the 30 studies in Shock, Septic by Assistance Publique - Hôpitaux de Paris, this one is the 12th largest by planned enrollment of the 17 interventional ones that give a count, is one of 3 that started in 2024, is one of 8 with no phase, reaches primary completion later than 3 of the 15 other live ones, and was the 21st registered.

Shock, Septic

1,084 studies on the registry are indexed under Shock, Septic; 236 are open to participants now.

Browse Shock, Septic studies →

Open to participants now

15 of the 30 studies in Shock, Septic by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Where they have run

Who these studies take

Of the 137 Shock, Septic studies recruiting now, 103 (75%) set no upper age limit and 18 (13%) stop at 75 or younger; 11 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Shock, Septic by Assistance Publique - Hôpitaux de Paris, or all of them as a file.
02

Study summary

Over-resuscitation including fluid overload has been associated with increased morbidity (prolonged duration of organ failure) and mortality in septic shock. "One-size-fits-all" resuscitation strategies may increase septic shock mortality. However, clinical studies on individualized resuscitation are lacking. Hemodynamic phenotyping may allow to individualize septic shock resuscitation. The ANDROMEDA-SHOCK trial found that a simple clinical and bedside CRT-targeted resuscitation reduces organ dysfunction and 28-day mortality in septic shock. The current study will examine the hypothesis that a CRT-targeted resuscitation based on hemodynamic phenotyping considering within an decision tree usual bedside clinical parameters such as pulse pressure, diastolic blood pressure, fluid responsiveness and cardiac performance can further decrease mortality in septic shock as compared to usual care.

Read the detailed description

Septic shock is associated with a high mortality risk related to progressive tissue hypoperfusion.However, despite extensive research on the best monitoring and resuscitation strategies, many uncertainties remain. Over-resuscitation, particularly when inducing fluid overload, might contribute to a worse outcome. Fluid overload more likely occurs when fluids are administered to fluid unresponsive patients, but also when inappropriate resuscitation goals are pursued, or a "one-size-fit all" strategy is followed. From a hemodynamic point of view, several pathogenic mechanisms determine a progressive circulatory dysfunction While loss of vascular tone and relative hypovolemia predominate in early phases, more complex mechanisms such as endothelial and microcirculatory dysfunction, progressive vasoplegia, and myocardial dysfunction may be involved later. In effect, from a clinical point of view, many patients despite been fluid loaded in pre-intensive care unit settings, are still evidently hypovolemic and benefit from further administration of fluid boluses. Others, however, present very low diastolic arterial pressures reflecting profound vasoplegia, and recent data suggest that these patients may benefit from early norepinephrine instead of fluids[; on the contrary, administering fluids may fail to correct vascular tone and increase the risk of fluid overload[2]. In addition, a recent echocardiography-based study confirms that a relevant myocardial dysfunction is present in a significant number of patients, and that several cardiovascular phenotypes with a potentially different therapeutic approach may be recognized[8]. Unfortunately, despite the availability of most of the parameters at the bedside and research efforts, no universally applicable clinical phenotyping method for septic shock patients has been translated to usual practice. This is particularly problematic since chocardiography is not immediately available in the majority of centers worldwide, and therefore initial decisions on fluid resuscitation are usually based on clinical grounds and tend to follow the one-size-fits-all principle, leading to the risk of fluid overload.

03

Conditions studied

  • Intensive Care Unit Acquired Weakness
  • Shock, Septic

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Consecutive adult patients (≥ 18 years)
  • Patients with septic shock according to Sepsis-3 consensus conference. In short, septic shock is defined as suspected or confirmed infection, plus hyperlactatemia and NE requirements due to persistent hypotension, after a fluid load of at least 1000mL in 1h
  • Patient and/or relative informed and having signed the information and consent form for participation in the study

Exclusion criteria

Exclusion Criteria:

  • More than 4 hours since septic shock diagnosis,
  • Anticipated surgery or acute hemodialysis procedure to start during the 6h intervention period
  • Active bleeding,
  • Do not resuscitate status,
  • Child B-C Cirrhosis
  • Underlying disease process with a \< 90 days and/or the attending clinician deems aggressive resuscitation unsuitable
  • shock (high risk of death within 24h)
  • Pregnancy
  • Concomitant severe acute respiratory distress syndrome
  • Patients in whom CRT cannot be accurately assessed
  • Non-affiliation to a social security scheme or to another social protection scheme
  • Patient on AME (state medical aid) (unless exemption from affiliation
  • Patient under legal protection (guardianship, curatorship)
  • Participation in another interventional study involving human participants or being in the exclusion period at the end of a previous study involving human participants, if applicable
  • Inability, according to the investigator, to understand the study (non-French-speaking patient, cognitive disorders)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
180 participants (estimated)

Study arms

  • No intervention
    Compartor arm

    - Patients allocated to the usual care group will be managed by the clinical staff according to usual practice at their sites including decisions about hemodynamic and perfusion monitoring, and all treatments, but should follow general recommendations of the Surviving Sepsis Campaign to avoid extremes of clinical practice. This includes basic hemodynamic targets such as a MAP \>65 mmHg, HR (heart rate) \<120 beats per minute (BPM), arterial oxygen saturation (SaO2) \>94%, Hb \> 7 gr/dl, and the use of NE as the first vasopressor and crystalloids as the fluid of choice.

  • Active comparator
    Capillary-refill time and phenotyping group

    Patients w/normal baseline CRT will be periodically monitored. Patients with abnormal CRT and septic shock will be categorized according to pulse pressure (PP). If \<40 mmHg, will go to fluid responsiveness (FR) assessment. FR (-) patients will undergo cardiac echo to rule out significant dysfunction. Fluid boluses will be administered in 30 min intervals and repeated as needed if CRT is still abnormal. Patients with PP ≥40 mmHg will proceed according to diastolic pressure (DAP). If ≥50 mmHg will move to FR assessment. If \<50 mmHg NE will be increased for MAP \>65 mmHg and DAP ≥50 mmHg w/CRT assessed 1 h after. NE will be increased in 0.1 mcg/k/m increments up to 0.5 mcg/k/m. If CRT is normal, patients will proceed to periodic monitoring. Patients with persistent abnormal CRT or that reached NE safety limit will proceed directly to echo. Patients that correct CRT with first tier interventions will not be subjected to obligatory echo but will just proceed to periodic monitoring.

    Other: Usual care (UC)

Interventions

  • OtherUsual care (UC)

    - Patients allocated to the UC group will be managed by the clinical staff according to usual practice at their sites including decisions about hemodynamic and perfusion monitoring, and all treatments, but should follow general recommendations of the Surviving Sepsis Campaign to avoid extremes of clinical practice. This includes basic hemodynamic targets such as a MAP \>65 mmHg, heart rate (HR) \<120 beats per minute (BPM), arterial oxygen saturation (SaO2) \>94%, Hb \> 7 gr/dl, and the use of NE as the first vasopressor and crystalloids as the fluid of choice.

06

What researchers measure

Primary outcomes

  1. A composite of all cause 28-days mortality plus time to cessation of vital support and length of hospital stay

    A hierarchical composite of all cause mortality within 28 days, time to cessation of vital support (truncated at 28 days) and length of hospital stay (truncated at 28 days).

    Time frame: 28 days

Secondary outcomes

  1. All-cause mortality within 28 days

    All-cause mortality within 28 days

    Time frame: 28 days

  2. Vital support free days

    The number of calendar days between randomization and 28 days that the patient is alive and with no requirement of cardiovascular, respiratory and renal support. Patients who die within 28 days will have zero days counted for this variable, irrespective of vital support status. Resolution of cardiovascular failure implies complete stopping of vasopressor support for at least 24 consecutive hours. Resolution of respiratory failure implies extubation / liberation from mechanical ventilation for at least 48 hours. Resolution of renal failure implies liberation of renal replacement therapy for at least 72 hours in those receiving continuous replacement modalities and at least 5 days for those receiving intermittent ones.

    Time frame: 28 days

  3. Length of hospital stay

    Number of days remaining hospitalized (from randomization up to hospital discharge), truncated at day 28.

    Time frame: 28 days

Other outcomes

  1. Length of ICU stay

    Number of days remaining in ICU (from randomization up to ICU discharge). Re-admission to ICU during follow-up period will be accounted for the original ICU length of stay only if occurred within the next week of ICU discharge and by a cause related with the original admission.

    Time frame: 28 days

  2. Time to cessation of vasopressor support

    The number of hours between randomization and complete stopping of vasopressor support (defined as its complete interruption for at least 24 consecutive hours), within 28 days from randomization

    Time frame: 28 days

  3. Time to cessation of mechanical ventilation

    The number of calendar days between intubation / start of mechanical ventilation and extubation / liberation from mechanical ventilation (maintained for at least 48 hours) within 28 days from randomization.

    Time frame: 28 days

  4. Time to cessation of renal replacement therapy

    The number of calendar days between start of renal replacement therapy and complete liberation from renal replacement therapy (at least 48 hours for continuous replacement modalities and 5 days for intermittent ones) within 28 days from randomization.

    Time frame: 28 days

  5. Vasopressor support-free days

    The number of calendar days without vasopressor support from randomization up to day 28. Cessation of vasopressor support implies its complete interruption for at least 24 consecutive hours.

    Time frame: 28 days

  6. Mechanical ventilation-free days

    The number of calendar days without mechanical ventilation support from randomization up to day 28. Cessation of mechanical ventilation support implies its complete interruption for at least 48 consecutive hours. Re-start of mechanical ventilation during follow-up period will be accounted for the original mechanical ventilation-free days only if this occurs within the next week of ICU discharge and by a cause related with the original admission.

    Time frame: 28 days

  7. Renal replacement therapy-free days

    The number of calendar days without renal replacement therapy from randomization up to day 28. Cessation of renal replacement therapy implies its complete interruption for at least 72 hours in those receiving continuous replacement modalities and at least 5 days for those receiving intermittent ones. Re-start of renal replacement therapy during follow-up period will be accounted for the original renal replacement-free days only if this occurs within the next week of ICU discharge and by a cause related with the original admission.

    Time frame: 28 days

  8. Variation in Sequential Organ Failure Assessment (SOFA) score

    The Sequential Organ Failure Assessment (SOFA) is used to track a patient's status during the stay in the ICU to determine the extent of organ dysfunction. Its values ranges from 0 to 24. Higher SOFA scores associate with a worse outcome. The SOFA score will be calculated upon the maximum values observed on the day of enrollment and then, at days 2, 3, 4, 5 and 7 (or until patient discharge or death, if this happened before day-7), using clinically available data. If an individual organ dysfunction value is not available (i.e., cardiovascular, respiratory, renal, etc.), it will be assumed to be zero unless previous value was abnormal (in which case it would be considered the same organ score). Neurological score under sedation/invasive mechanical ventilation will be computed as that observed just before sedation/intubation.

    Time frame: 7 days

  9. Variation of creatinine-based KDIGO stage

    Renal function assessed according to "Kidney Disease: Improving Global Outcomes (KDIGO) staging system from randomization through day 7 to assess for "de novo" or "worsening" acute kidney injury. Patients under chronic renal replacement therapy will not meet this end-point

    Time frame: 7 days

  10. Volume of resuscitation fluids

    The volume of fluids administered with resuscitative intention up to 72 hours from randomization.

    Time frame: 72 hours

  11. Net fluid balance

    The volume of cumulated fluids during the first 72 hours from randomization.

    Time frame: 72 hours

  12. Evolvement of capillary refill time (CRT)

    Evolvement of CRT within the first 72 hours after randomization.

    Time frame: 72 hours

  13. Evolvement of lactate levels

    Evolvement of arterial lactate levels within the first 72 hours after randomization.

    Time frame: 72 hours

  14. Evolvement of central venous pressure

    Evolvement of Central venous pressure within the first 72 hours after randomization.

    Time frame: 72 hours

  15. Evolvement of central venous oxygen saturation

    Evolvement of central venous oxygen saturation within the first 72 hours after randomization

    Time frame: 72 hours

  16. Evolvement of central venous to arterial carbon dioxide difference

    Evolvement of central venous to arterial carbon dioxide difference within the first 72 hours after randomization.

    Time frame: 72 hours

  17. All-cause mortality within 90 days

    All-cause mortality within 90 days

    Time frame: 90 days

  18. Length of hospital stay

    Number of days remaining hospitalized (from randomization up to hospital discharge), truncated at day 90.

    Time frame: 90 days

  19. Changes in CRT before and after fluid resuscitation or increase in norepinephrine

    Assess the changes in CRT before and after fluid resuscitation or increase in norepinephrine doses and analyse their correlation with changes in haemodynamic parameters: systolic arterial pressure (SAP), diastolic arterial pressure (DAP), mean arterial pressure (MAP), pulse pressure (PP), cardiac output (CO) when available.

    Time frame: 72 hours

07

Study locations

1 of 1 sites recruiting
  • Hôpital Robert Debré, Université de Reims
    Reims, 51092, France
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for Dec 2025, 21 months after the start.

Of 165 non-industry interventional studies with no phase under Shock, Septic, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 41. This study's planned 21 months is below that.

Counting every sponsor, half of 173 studies reached it within 25 months; a quarter within 12 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2023
First posted
Oct 2, 2023
StartActual
Feb 6, 2024
Primary completionEst.
Dec 1, 2025
CompletionEst.
May 30, 2026
Last update
Dec 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06062303
Responsible party
Sponsor
First posted
Oct 2, 2023
Start date
Feb 6, 2024
Primary completion
Dec 1, 2025 (estimated)
Completion
May 30, 2026 (estimated)
Last update
Dec 5, 2024

Study contacts

Olfa MD Hamzaoui, PhD
Contact
ohamzaoui@chu-reims.fr
0033310736973

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion